# Balchem Corporation

> Balchem develops, manufactures and sells specialty ingredients and delivery technologies for food, supplements, animal feed, plant nutrition and industrial applications. Its branded nutrients, microencapsulation and formulation expertise help manufacturers control ingredient stability, release, taste and performance. The Nasdaq-listed company reported $1.037 billion in 2025 sales.

- **Founded:** 1967
- **Headquarters:** Montvale, United States
- **Founders:** Leslie Balassa (Co-founder; encapsulation expert)
- **Products:** VitaCholine, ReaShure, Albion Minerals, K2VITAL, OptiMSM
- **Notable:** Publicly traded since 1970; Nasdaq ticker BCPC., Reported 2025 net sales of $1.037 billion and GAAP net earnings of $154.8 million., Reported 2025 operating cash flow of $216.6 million.

## Products & services

- **VitaCholine** — Branded choline ingredients for human nutrition, including food, supplement and infant-nutrition applications.
- **ReaShure** — Encapsulated choline designed to resist rumen degradation and deliver choline to the small intestine in dairy cattle.
- **Albion Minerals** — Chelated minerals and mineral complexes for nutritional formulations; acquired in 2016.
- **K2VITAL** — Vitamin K2 ingredient platform added through the Kappa Bioscience acquisition.
- **OptiMSM** — Methylsulfonylmethane ingredient brand added through Bergstrom Nutrition.
- **Optifolin+** — Choline-enriched folate combining L-5-MTHF with choline; debuted at SupplySide West 2024.
- **BakeShure, ConfecShure, MeatShure and VitaShure** — Encapsulated ingredients that control release and address processing, stability, flavor and shelf-life requirements.
- **Metalosate** — Chelated mineral micronutrients for agricultural plant nutrition.
- **Performance Gases** — Specialty packaging and distribution of gases for medical-device sterilization, fumigation, refrigeration and industrial applications.
- **Ingredient formulation and particle engineering** — Custom food and beverage systems, blending, spray drying, agglomeration and application development.

## Achievements

- Publicly traded since 1970; Nasdaq ticker BCPC.
- Reported 2025 net sales of $1.037 billion and GAAP net earnings of $154.8 million.
- Reported 2025 operating cash flow of $216.6 million.
- Global footprint includes 22 manufacturing locations and eight technology centers.
- Acquired Albion in 2016 and Kappa Bioscience in 2022.

## Latest updates

- **2026-10** — On October 23, Balchem reported Q3 net sales of $290.7 million, GAAP net earnings of $46.7 million and adjusted EBITDA of $80.3 million. Percentage growth figures in the website release conflict with comparative financial tables, so they are omitted here.
- **2026-07** — Amended revolving credit facility increased permitted borrowing to $650 million and extended maturity to July 24, 2031.
- **2026-02** — Full-year 2025 results included $1.037 billion in sales and $173.6 million in free cash flow, a company-reported non-GAAP measure.

## Links

- Website: https://balchem.com/
- LinkedIn: https://www.linkedin.com/company/balchem-corporation
- Twitter/X: https://twitter.com/balchemcorp
- YouTube: https://www.youtube.com/@BalchemANH
- Instagram: https://www.instagram.com/balchem.hnh/
- Facebook: https://www.facebook.com/BalchemCorp/

---

Profile page: https://yespress.io/balchem-corporation
Published by YesPress — https://yespress.io
Last updated: 2026-10-24